Data on AVEO Pharmaceuticals, Inc.'s AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at American Association for Cancer Research 100th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present during two educational sessions, nine poster sessions and a minisymposium at the American Association for Cancer Research (AACR) 100th Annual Meeting on April 18-22, 2009, in Denver, Colorado.
MORE ON THIS TOPIC